The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial

AIM OF THE STUDY: The BRAF inhibitor vemurafenib has improved progression-free survival and overall survival in patients with BRAFV600-mutation-positive metastatic melanoma. Here we present the results of an open-label safety study with vemurafenib in patients with metastatic melanoma enrolled in Po...

Descripción completa

Detalles Bibliográficos
Autores principales: Rutkowski, Piotr, Kozak, Katarzyna, Mackiewicz, Jacek, Krzemieniecki, Krzysztof, Nawrocki, Sergiusz, Wasilewska-Teśluk, Ewa, Kwinta, Łukasz, Wysocki, Piotr, Koseła-Paterczyk, Hanna, Świtaj, Tomasz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2015
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631301/
https://www.ncbi.nlm.nih.gov/pubmed/26557775
http://dx.doi.org/10.5114/wo.2015.54082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631301/
https://www.ncbi.nlm.nih.gov/pubmed/26557775
http://dx.doi.org/10.5114/wo.2015.54082

Ejemplares similares